Risk of Second Cancers after Treatment for Hodgkin's Disease

New England Journal of Medicine

Volumn 318, Issue 2, 1988, Pages 76-81

  Tucker, M A ^a,b   Coleman, C N ^a,b   Cox, R S ^a,b   Varghese, A ^a,b   Rosenberg, S A ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; COLLOIDAL GOLD; DACARBAZINE; DOXORUBICIN; MELPHALAN; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CHILD; FEMALE; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0023835089     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198801143180203     Document Type: Article

References (41)

1. Coleman CN. Kaplan HS, Cox R. Varghese A, Butterfield P, Rosenberg SA. Leukemias, non-Hodgkin's Iymphomas and solid tumors in patients treated for Hodgkin's disease. Cancer Surv 1982; 1: 733–44.
2. Valagussa P, Santoro A, Fossati-Bellani F, Banfi A, Bonadonna G. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 1986; 4: 830–7.
3. Tester WJ, Kinsella TJ, Waller B, et al. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. J Clin Oncol 1984; 2: 762–9.
4. Coltman CA Jr, Dixon DO. Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year follow-up. Cancer Treat Rep 1982; 66: 1023–33.
5. Pedersen-Bjergaard J, Larsen SO. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment for Hodgkin's disease. N Engl J Med 1982; 307: 965–71.
6. Boivin J-F, Hutchison GB, Lyden M, Godbold J, Chorosh J, Schottenfeld D. Second primary cancers following treatment of Hodgkin's disease. JNCI 1984; 72: 233–41.
7. Blayney DW, Longo DL, Young RC, et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987; 316: 710–4.
8. Krikorian JG, Burke JS, Rosenberg SA, Kaplan HS. Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease. N Engl J Med 1979; 300: 452–8.
9. Tucker MA. Misfeldt D, Coleman CN, Clark WH Jr, Rosenberg SA. Cutaneous malignant melanoma after Hodgkin's disease. Ann Intern Med 1985; 102: 37–41.
10. Coleman CN, Burke JS, Varghese A, Rosenberg SA, Kaplan HS. Secondary leukemia and non-Hodgkin's lymphoma in patients treated for Hodgkin's disease. In: Rosenberg SA, Kaplan HS, eds. Advances in malignant Iymphomas. New York: Academic Press, 1982:259–75.
11. DeVita VT, Serpick AA, Carbone pp. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970; 73: 881–95.
12. Thompson JM, Horning SJ, Hoppe RT, Wolin EM, Kaplan HS, Rosenberg SA. Current Stanford results utilizing MOP(P) vs PAVe as adjuvant chemotherapy for Hodgkin's disease. Proc Am Soc Clin Oncol 1983; 2: 212. abstract.
13. Horning SJ, Hoppe RT, Rosenberg SA. VBM chemotherapy: an effective adjuvant to involved field irradiation in favorable Hodgkin's disease (HD). Proc Am Soc Clin Oncol 1986; 5: 198. abstract.
14. Kraut JW, Kaplan HS, Bagshaw MA. Combined fractionated isotopic and external irradiation of the liver in Hodgkin's disease: a study of 21 patients. Cancer 1972; 30: 39–46.
15. Monson RR. Analysis of relative survival and proportional mortality. Comput Biomed Res 1974; 7: 325–32.
16. Heston JF, Kelly JAB, Meigs JW, Flannery JT, Cusano MM, Young JL Jr. Forty-five years of cancer incidence in Connecticut: 1935–79. Natl Cancer Inst Monogr 1986; 70: 338.
17. Rothman KJ, Boice JD Jr. Epidemiologic analysis with a programmable calculator. Washington, D.C.: Government Printing Office, 1979. (DHEW publication no. 79–1649.)
18. Breslow NE, Lubin JH, Marek P, Langholz D. Multiplicative models and cohort analysis. J Am Stat Assoc 1983; 78: 1–12.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457–81.
20. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965; 52: 203–23.
21. van Leeuwen FE, Somers R, Hart AAM. Splenectomy in Hodgkin's disease and second leukaemias. Lancet 1987; 2: 210–1.
22. List AF, Doll DC, Greco FA. Lung cancer in Hodgkin's disease: association with previous radiotherapy. J Clin Oncol 1985; 3: 215–21.
23. National Academy of Sciences. The effects on populations of exposure to low levels of ionizing radiation: 1980. Washington, D.C.: National Academy Press, 1980.
24. Tucker MA, Fraumeni JF Jr. Soft tissue. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer epidemiology and prevention. Philadelphia: W.B. Saunders, 1982:827–36.
25. Tucker MA, D'Angio GJ, Boice JD Jr. et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317: 588–93.
26. Boice JD Jr, Monson RR. Breast cancer in women after repeated fluoroscopic examinations of the chest. JNCI 1977; 59: 823–32.
27. Pretorius HT, Katikineni M, Kinsella TJ, et al. Thyroid nodules after high-dose external radiotherapy: fine-needle aspiration cytology in diagnosis and management. JAMA 1982; 247: 3217–20.
28. Tucker MA, Meadows AT, Morris Jones P, Stovall M. Therapeutic radiation at young age linked to secondary thyroid cancer. Proc Am Soc Clin Oncol 1986; 5: 211. abstract.
29. Blattner WA, Hoover RN. Cancer in the immunosuppressed host. In: DeVita VT Jr, Heilman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 2nd ed. Philadelphia: J.B. Lippincott, 1985:1999–2006.
30. Kinlen LJ, Immunologic factors. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer epidemiology and prevention. Philadelphia: W.B. Saunders, 1982:494–505.
31. Fraumeni JF Jr, Hoover RN. Immunosurveillance and cancer: epidemiologic observations. Natl Cancer Inst Monogr 1977; 47: 121–6.
32. Takenaka T, Sakano T, Kitahara T. Kitaska H, Watanabe S, Hirota T. Five cases of malignant lymphoma associated with early gastric cancer. Jpn J Clin Oncol 1978; 8: 209–17.
33. Greene MH, Wilson J. Second cancer following lymphatic and hematopoietic cancers in Connecticut, 1935–82. Natl Cancer Inst Monogr 1985; 18: 191–217.
34. Kaplan HS, ed. Hodgkin's disease. 2nd ed. Cambridge, Mass.: Harvard University Press, 1980:236–79.
35. List AF, Greer JP, Consar JB, et al. Non-Hodgkin's lymphoma after treatment of Hodgkin's disease: association with Epstein–Barr virus. Ann Intern Med 1986; 105: 668–73.
36. Tucker MA, Meadows AT, Boice JD Jr, et al. Leukemia after therapy with alkylating agents for childhood cancer. JNCI 1987; 78: 459–64.
37. Greene MH, Harris EL, Gershenson DM, et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med 1986; 105: 360–7.
38. Horning SJ, Hoppe RT, Kaplan HS, Rosenberg SA. Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med 1981; 304: 1377–82.
39. Sherins RJ, DeVita VT Jr. Effect of drug treatment for lymphoma on male reproductive capacity: studies of men in remission after therapy. Ann Intern Med 1973; 79: 216–20.
40. Rosenberg SA, Kaplan HS. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962–1984. Int J Radit Oncol Biol Phys 1985; 11: 5–22.
41. Bookman MA, Longo DL. Concomitant illness in patients treated for Hodgkin's disease. Cancer Treat Rev 1986; 13: 77–111.